Citations (130)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (32)
Yanling Ding, Lina Sun, Ying Wang, Jing Zhang & Yahong Chen. (2022) Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 1051-1067.
Read now
Read now
Thomas P Lodise, Jingyi Li, Hitesh N Gandhi, Gerald O’Brien & Sanjay Sethi. (2020) Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 2889-2900.
Read now
Read now
Claudio Tantucci & Laura Pini. (2020) Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 821-829.
Read now
Read now
Bin Tang, Jun Wang, Lin-lin Luo, Qiu-gen Li & Dan Huang. (2019) Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 757-766.
Read now
Read now
Adamantia Liapikou, Catia Cilloniz & Antoni Torres. (2018) Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opinion on Drug Safety 17:10, pages 991-1003.
Read now
Read now
José Luis Izquierdo & Borja G Cosio. (2018) The dose of inhaled corticosteroids in patients with COPD: when less is better. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3539-3547.
Read now
Read now
Kylie BR Belchamber, Catherine MR Thomas, Amy E Dunne, Peter J Barnes & Louise E Donnelly. (2018) Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 2883-2897.
Read now
Read now
Christer Janson, Georgios Stratelis, Anna Miller-Larsson, Tim W Harrison & Kjell Larsson. (2017) Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3055-3064.
Read now
Read now
Rupert Jones, Jessica Martin, Vicky Thomas, Derek Skinner, Jonathan Marshall, Martina Stagno d’Alcontres & David Price. (2017) The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2445-2454.
Read now
Read now
Mike Thomas, David MG Halpin & Marc Miravitlles. (2017) When is dual bronchodilation indicated in COPD?. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2291-2305.
Read now
Read now
A Papi, D Dokic, W Tzimas, I Mészáros, A Olech-Cudzik, Z Koroknai, K McAulay, S Mersmann, PS Dalvi & T Overend. (2017) Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1961-1971.
Read now
Read now
Silvia Cascini, Ursula Kirchmayer, Valeria Belleudi, Lisa Bauleo, Riccardo Pistelli, Mirko Di Martino, Giulio Formoso, Marina Davoli & Nera Agabiti. (2017) Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and Risk of Pneumonia: A Nested Case-Control Population-based Study in Lazio (Italy)—The OUTPUL Study. COPD: Journal of Chronic Obstructive Pulmonary Disease 14:3, pages 311-317.
Read now
Read now
Mingjin Yang, Hong Chen, Yan Zhang, Yuejun Du, Ying Xu, Ping Jiang & Zhibo Xu. (2017) Long-term use of inhaled corticosteroids and risk of upper respiratory tract infection in chronic obstructive pulmonary disease: a meta-analysis. Inhalation Toxicology 29:5, pages 219-226.
Read now
Read now
Emir Festic, Vikas Bansal, Ena Gupta & Paul D. Scanlon. (2016) Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic Review and Meta-Analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease 13:3, pages 312-326.
Read now
Read now
Thomas R. Einarson, Basil G. Bereza, T. Anders Nielsen, Jan Van Laer & Michiel E. H. Hemels. (2016) Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD. Journal of Medical Economics 19:4, pages 319-355.
Read now
Read now
Ian A. Yang, Janet G. Shaw, John R. Goddard, Melissa S. Clarke & David W. Reid. (2016) Use of inhaled corticosteroids in COPD: improving efficacy. Expert Review of Respiratory Medicine 10:3, pages 339-350.
Read now
Read now
M. H. Roberts, M. E. Borrego, A. A. Kharat, P. L. Marshik & D. W. Mapel. (2016) Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 167-192.
Read now
Read now
Adamantia Liapikou, Michael Toumbis & Antoni Torres. (2015) Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. Expert Opinion on Drug Safety 14:8, pages 1237-1247.
Read now
Read now
Alberto Papi, Paul W Jones, Prashant S Dalvi, Kirsten McAulay, Tammy McIver & Sanjeeva Dissanayake. (2015) The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 2431-2438.
Read now
Read now
Kazuhisa Asai, Akihiro Kobayashi, Yukio Makihara & Malcolm Johnson. (2015) Anti-inflammatory effects of salmeterol/fluticasone propionate 50/250 mcg combination therapy in Japanese patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 803-811.
Read now
Read now
Maria Gabriella Matera, Vittorio Cardaci, Mario Cazzola & Paola Rogliani. (2015) Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opinion on Drug Safety 14:4, pages 533-541.
Read now
Read now
Dana S. Mowls, Vinay K. Cheruvu, Robert Schilz & Melissa D. Zullo. (2015) COPD in a Nationally Representative Sample: Sociodemographic Factors and Co-morbidity, Diagnosis Method, and Healthcare Utilization. COPD: Journal of Chronic Obstructive Pulmonary Disease 12:1, pages 96-103.
Read now
Read now
Shih-Lung Cheng, Kang-Cheng Su, Hao-Chien Wang, Diahn-Warng Perng & Pan-Chyr Yang. (2014) Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Design, Development and Therapy 8, pages 601-607.
Read now
Read now
Yuji Oba & Nazir A Lone. (2014) Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 469-479.
Read now
Read now
Ruben D Restrepo, Andrew Tate & Joshua Coquat. (2013) Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 14:14, pages 1993-2002.
Read now
Read now
Esther Antón. (2013) How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease?. Expert Review of Respiratory Medicine 7:sup2, pages 25-32.
Read now
Read now
Edward M. Kerwin, Anthony D. D'Urzo, Arthur F. Gelb, Hassan Lakkis, Esther Garcia Gil & Cynthia F. Caracta. (2012) Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I). COPD: Journal of Chronic Obstructive Pulmonary Disease 9:2, pages 90-101.
Read now
Read now
Anand A Dalal, Manan Shah, Anna O D’Souza, Sham Chaudhari & Glenn Crater. (2012) Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 11-19.
Read now
Read now
Edward J Mills, Eric Druyts, Isabella Ghement & Milo A Puhan. (2011) Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clinical Epidemiology 3, pages 107-129.
Read now
Read now
Douglas W Mapel, Anand A Dalal, Christopher M Blanchette, Hans Petersen & Gary T Ferguson. (2011) Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. International Journal of Chronic Obstructive Pulmonary Disease 6, pages 573-581.
Read now
Read now
Barbara P Yawn, Ibrahim Raphiou, Judith S Hurley & Anand A Dalal. (2010) The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. International Journal of Chronic Obstructive Pulmonary Disease 5, pages 165-178.
Read now
Read now
Anand A Dalal, Meaghan St Charles, Hans V Petersen, Melissa H Roberts, Christopher M Blanchette & Kathy Manavi-Zieverink. (2010) Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 5, pages 179-187.
Read now
Read now
Articles from other publishers (98)
Shisheng Peng, Cong Tan, Lirong Du, Yanan Niu, Xiansheng Liu & Ruiying Wang. (2023) Effect of fracture risk in inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulmonary Medicine 23:1.
Crossref
Crossref
Keiji Oishi, Kazuto Matsunaga, Tasuku Yamamoto, Kazuki Matsuda, Yoriyuki Murata & Tsunahiko Hirano. (2023) Practical Recommendations for a Selection of Inhaled Corticosteroids in COPD: A Composite ICO Chart. Biomolecules 13:2, pages 213.
Crossref
Crossref
Hong Chen, Zheng-Xu Deng, Jian Sun, Qiang Huang, Lan Huang, Yong-Hong He, Chunlan Ma & Ke Wang. (2023) Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD. Chest 163:1, pages 100-114.
Crossref
Crossref
Mary Ashley Brown, Maisha Jabeen, Gurpreet Bharj & Timothy S.C. Hinks. (2022)
Non-typeable
Haemophilus influenzae
airways infection: the next treatable trait in asthma?
. European Respiratory Review 31:165, pages 220008.
Crossref
Crossref
Borja G. Cosío, Hanaa Shafiek & Miguel Ángel Martínez-García. (2022) Is it Time to Readjust the Doses of Inhaled Corticosteroids in COPD?. Archivos de Bronconeumología 58:8, pages 593-594.
Crossref
Crossref
Josefin Eklöf, Truls Sylvan Ingebrigtsen, Rikke Sørensen, Mohamad Isam Saeed, Imane Achir Alispahic, Pradeesh Sivapalan, Jonas Bredtoft Boel, Jette Bangsborg, Christian Ostergaard, Ram Benny Dessau, Ulrich Stab Jensen, Ejvind Frausing Hansen, Therese Sophie Lapperre, Howraman Meteran, Torgny Wilcke, Niels Seersholm & Jens-Ulrik Stæhr Jensen. (2022)
Use of inhaled corticosteroids and risk of acquiring
Pseudomonas aeruginosa
in patients with chronic obstructive pulmonary disease
. Thorax 77:6, pages 573-580.
Crossref
Crossref
浩 杨. (2022) Research Progress on Discontinuation of ICS with Triple Inhaled Drugs for Chronic Obstructive Pulmonary Disease. Advances in Clinical Medicine 12:07, pages 6963-6974.
Crossref
Crossref
Robert A. Wise, Mona Bafadhel, Courtney Crim, Gerard J. Criner, Nicola C. Day, David M.G. Halpin, MeiLan K. Han, Peter Lange, David A. Lipson, Fernando J. Martinez, Diego J. Maselli, Dawn Midwinter, Dave Singh, Maeva Zysman, Mark T. Dransfield & Richard E.K. Russell. (2021) Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review 30:162, pages 210124.
Crossref
Crossref
Marc Miravitlles, Ariadna Auladell-Rispau, Mònica Monteagudo, Juan Carlos Vázquez-Niebla, Jibril Mohammed, Alexa Nuñez & Gerard Urrútia. (2021) Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. European Respiratory Review 30:160, pages 210075.
Crossref
Crossref
Hong Chen, Jian Sun, Qiang Huang, Yongqi Liu, Mengxin Yuan, Chunlan Ma & Hao Yan. (2021) Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. Frontiers in Pharmacology 12.
Crossref
Crossref
Benjamin F. Hartley, Neil C. Barnes, Sally Lettis, Chris H. Compton, Alberto Papi & Paul Jones. (2020) Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respiratory Research 21:1.
Crossref
Crossref
Hong Chen, Yulin Feng, Ke Wang, Jing Yang & Yuejun Du. (2020) Association between inhaled corticosteroids and upper respiratory tract infection in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. BMC Pulmonary Medicine 20:1.
Crossref
Crossref
Claus F. Vogelmeier, Anne Fuhlbrigge, Alexandra Jauhiainen, Lieke E.J.M. Scheepers, Thomas Bengtsson, Stefan Peterson, Niklas Karlsson, Tariq Sethi, Nicholas Locantore, Ruth Tal-Singer, Stephen Rennard, Malin Fagerås & Carla A. Da Silva. (2020) COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development. Respiratory Medicine 173, pages 106175.
Crossref
Crossref
Takudzwa Mkorombindo & Mark T. Dransfield. (2020) Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine 41:3, pages 475-484.
Crossref
Crossref
Sakinatus Syarifah & Muhammad Amin. (2020) Penggunaan Extrafine Beclometason Diproprionat/Formoterol Fumarat pada PPOK. Jurnal Respirasi 5:2, pages 47.
Crossref
Crossref
Nicola A. Hanania, Alberto Papi, Antonio Anzueto, Fernando J. Martinez, Kimberly A. Rossman, Christy S. Cappelletti, Elizabeth A. Duncan, Jack S. Nyberg & Paul M. Dorinsky. (2020) Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD. ERJ Open Research 6:2, pages 00187-2019.
Crossref
Crossref
Nevin Kishore, Saibal Moitra & Mrinal Sircar. (2020)
Management of chronic obstructive pulmonary disease: Insights into patient profile – Use of inhaled corticosteroids/long-acting β
2
-Agonists or long-acting β
2
-agonists/long-acting muscarinic antagonists
. Indian Journal of Respiratory Care 9:2, pages 162.
Crossref
Crossref
Mingjin Yang, Yuejun Du, Hong Chen, Depeng Jiang & Zhibo Xu. (2019) Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. International Immunopharmacology 77, pages 105950.
Crossref
Crossref
Hannah A. Blair. (2019) Fluticasone propionate/salmeterol (Wixela® Inhub®) dry-powder inhaler in asthma and COPD: a profile of its use in the USA. Drugs & Therapy Perspectives 35:12, pages 583-591.
Crossref
Crossref
Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, Roopa Trivedi, Earl St Rose, Shaila Ballal, Julie McLaren, Patrick Darken, Colin Reisner & Paul Dorinsky. (2019) A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory Medicine 158, pages 59-66.
Crossref
Crossref
Samy Suissa. (2019) Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias?. European Respiratory Journal 53:2, pages 1802112.
Crossref
Crossref
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Christer Janson, Gunnar Johansson, Björn Ställberg, Karin Lisspers, Petter Olsson, Dorothy L. Keininger, Milica Uhde, Florian S. Gutzwiller, Leif Jörgensen & Kjell Larsson. (2018) Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respiratory Research 19:1.
Crossref
Crossref
Adolfo Baloira, José Miguel Rodriguez Gonzalez-Moro, Estefanía Sanjuán, Juan Antonio Trigueros & Ricard Casamor. (2018) Degree of control of patients with chronic obstructive pulmonary disease in Spain: SINCON study. BMC Pulmonary Medicine 18:1.
Crossref
Crossref
Alvar Agusti, Leonardo M. Fabbri, Dave Singh, Jørgen Vestbo, Bartolome Celli, Frits M.E. Franssen, Klaus F. Rabe & Alberto Papi. (2018) Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal 52:6, pages 1801219.
Crossref
Crossref
Bartolome R. Celli. (2018) Pharmacological Therapy of COPD. Chest 154:6, pages 1404-1415.
Crossref
Crossref
Gary T. Ferguson, Alberto Papi, Antonio Anzueto, Edward M. Kerwin, Christy Cappelletti, Elizabeth A. Duncan, Jack Nyberg & Paul Dorinsky. (2018) Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. European Respiratory Journal 52:3, pages 1801334.
Crossref
Crossref
Hideki Yasui, Naoki Inui, Tomoyuki Fujisawa, Masato Karayama, Noriyuki Enomoto, Yutaro Nakamura, Shigeki Kuroishi, Hisano Ohba, Koshi Yokomura, Jun Sato, Masaki Sato, Naoki Koshimizu, Mikio Toyoshima, Takashi Yamada, Masafumi Masuda, Toshihiro Shirai & Takafumi Suda. (2018) Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 12, pages 117954841877170.
Crossref
Crossref
Ram B Sah & Anchal Teotiya. (2017)
Evaluation of Sleep Disorders in Chronic Obstructive Pulmonary Disease Patients by Subjective Questionnaire and Their Correlation with FEV1, PaO
2
, and PaCO
2
. Indian Journal of Sleep Medicine 12:4, pages 60-63.
Crossref
Crossref
Gary T. Ferguson, Donald P. Tashkin, Tor Skärby, Carin Jorup, Kristina Sandin, Michael Greenwood, Kristine Pemberton & Frank Trudo. (2017) Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respiratory Medicine 132, pages 31-41.
Crossref
Crossref
Courtney Crim, Peter M.A. Calverley, Julie A. Anderson, Andrew P. Holmes, Sally Kilbride, Fernando J. Martinez, Robert D. Brook, David E. Newby, Julie C. Yates, Bartolomé R. Celli & Jørgen Vestbo. (2017) Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respiratory Medicine 131, pages 27-34.
Crossref
Crossref
Jaymin B. Morjaria, Alan Rigby & Alyn H. Morice. (2017) Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. Lung 195:3, pages 281-288.
Crossref
Crossref
G. Jébrak, P.-R. Burgel, D. Caillaud, G. Deslée, G. Brinchault, P. Chanez, I. Court-Fortune, R. Escamilla, P. Nesme-Meyer, C. Pinet, T. Perez, J.-L. Paillasseur & N. Roche. (2017) Évolution des traitements de fond entre 2001 et 2012 chez les patients atteints de BPCO en France. Impact de la mise à disposition des anticholinergiques de longue durée d’action. Revue des Maladies Respiratoires 34:5, pages 535-543.
Crossref
Crossref
Marc Miravitlles, Anthony D’Urzo, Dave Singh & Vladimir Koblizek. (2016) Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respiratory Research 17:1.
Crossref
Crossref
Amber L. Martin, Jessica Marvel, Kyle Fahrbach, Sarah M. Cadarette, Teresa K. Wilcox & James F. Donohue. (2016) The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis. Respiratory Research 17:1.
Crossref
Crossref
Peter M. A. Calverley, Stephen I. Rennard, Emmanuelle Clerisme-Beaty, Norbert Metzdorf, Valentina Bayer Zubek & Richard ZuWallack. (2016) Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD. Respiratory Research 17:1.
Crossref
Crossref
Timothy S. C. Hinks, Joshua C. Wallington, Anthony P. Williams, Ratko Djukanović, Karl J. Staples & Tom M. A. Wilkinson. (2016)
Steroid-induced Deficiency of Mucosal-associated Invariant T Cells in the Chronic Obstructive Pulmonary Disease Lung. Implications for Nontypeable
Haemophilus influenzae
Infection
. American Journal of Respiratory and Critical Care Medicine 194:10, pages 1208-1218.
Crossref
Crossref
Editorial Article. (2016) Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 2). PULMONOLOGIYA 26:3, pages 267-291.
Crossref
Crossref
Rui Chen, Jing-wei Tian, Lu-qian Zhou, Xin Chen, Hai-yan Yan, Bin Zeng & Ming-sheng Zhang. (2016) The relationship between sleep quality and functional exercise capacity in COPD. The Clinical Respiratory Journal 10:4, pages 477-485.
Crossref
Crossref
Dave Singh, Massimo Corradi, Monica Spinola, Stefano Petruzzelli & Alberto Papi. (2016) Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. npj Primary Care Respiratory Medicine 26:1.
Crossref
Crossref
Hernan Iannella, Carlos Luna & Grant Waterer. (2016) Inhaled corticosteroids and the increased risk of pneumonia: what’s new? A 2015 updated review. Therapeutic Advances in Respiratory Disease 10:3, pages 235-255.
Crossref
Crossref
Adrian Gillissen, Peter Haidl, Martin Kohlhäufl, Klaus Kroegel, Thomas Voshaar & Christian Gessner. (2016) The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Deutsches Ärzteblatt international.
Crossref
Crossref
Christian Röver, Stefan Andreas & Tim Friede. (2015) Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data. Biometrical Journal 58:1, pages 170-185.
Crossref
Crossref
Lancelot M Pinto, Majed Alghamdi, Andrea Benedetti, Tasneem Zaihra, Tara Landry & Jean Bourbeau. (2015) Derivation and validation of clinical phenotypes for COPD: a systematic review. Respiratory Research 16:1.
Crossref
Crossref
David A Scott, Bethan Woods, Juliette C Thompson, James F Clark, Neil Hawkins, Mike Chambers, Bartolome R. Celli & Peter Calverley. (2015) Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulmonary Medicine 15:1.
Crossref
Crossref
Ming-Chia Lee, Chih-Hsin Lee, Shu-Chen Chien, Jer-Hwa Chang, Han-Lin She, Jann-Yuan Wang & Ming-Chih Yu. (2015) Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease. Medicine 94:42, pages e1723.
Crossref
Crossref
James F. Donohue, Sally Worsley, Chang-Qing Zhu, Liz Hardaker & Alison Church. (2015) Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respiratory Medicine 109:7, pages 870-881.
Crossref
Crossref
Gerard J. Criner, Jean Bourbeau, Rebecca L. Diekemper, Daniel R. Ouellette, Donna Goodridge, Paul Hernandez, Kristen Curren, Meyer S. Balter, Mohit Bhutani, Pat G. Camp, Bartolome R. Celli, Gail Dechman, Mark T. Dransfield, Stanley B. Fiel, Marilyn G. Foreman, Nicola A. Hanania, Belinda K. Ireland, Nathaniel Marchetti, Darcy D. Marciniuk, Richard A. Mularski, Joseph Ornelas, Jeremy D. Road & Michael K. Stickland. (2015) Prevention of Acute Exacerbations of COPD. Chest 147:4, pages 894-942.
Crossref
Crossref
Pierre Ernst, Nathalie Saad & Samy Suissa. (2015) Inhaled corticosteroids in COPD: the clinical evidence. European Respiratory Journal 45:2, pages 525-537.
Crossref
Crossref
Emir Festic & Paul D. Scanlon. (2015) Incident Pneumonia and Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Double Effect of Inhaled Corticosteroids?. American Journal of Respiratory and Critical Care Medicine 191:2, pages 141-148.
Crossref
Crossref
. (2015) Sleep disorders in chronic obstructive pulmonary disease. Indian Journal of Sleep Medicine 10:1, pages 11-21.
Crossref
Crossref
Courtney Crim, Mark T. Dransfield, Jean Bourbeau, Paul W. Jones, Nicola A. Hanania, Donald A. Mahler, Jørgen Vestbo, Andrew Wachtel, Fernando J. Martinez, Frank Barnhart, Sally Lettis & Peter M. A. Calverley. (2015) Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. Annals of the American Thoracic Society 12:1, pages 27-34.
Crossref
Crossref
Felix J.F. Herth, Peter Bramlage & Dirk Müller-Wieland. (2015) Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease. Respiration 89:1, pages 66-75.
Crossref
Crossref
Anthony D D’Urzo, Stephen I Rennard, Edward M Kerwin, Victor Mergel, Anne R Leselbaum & Cynthia F Caracta. (2014) Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respiratory Research 15:1.
Crossref
Crossref
Jill A Ohar, Glenn D Crater, Amanda Emmett, Thomas J Ferro, Andrea N Morris, Ibrahim Raphiou, Peruvemba S Sriram & Mark T Dransfield. (2014) Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation. Respiratory Research 15:1.
Crossref
Crossref
Dave Singh, Gabriele Nicolini, Eddi Bindi, Massimo Corradi, Daniele Guastalla, Jorg Kampschulte, Władysław Pierzchała, Abdullah Sayiner, Mária Szilasi, Claudio Terzano & Jørgen Vestbo. (2014) Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD. BMC Pulmonary Medicine 14:1.
Crossref
Crossref
Christopher E Brightling, Eugene R Bleecker, Reynold A PanettieriJrJr, Mona Bafadhel, Dewei She, Christine K Ward, Xiao Xu, Claire Birrell & René van der Merwe. (2014) Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. The Lancet Respiratory Medicine 2:11, pages 891-901.
Crossref
Crossref
Lydia Finney, Matthew Berry, Aran Singanayagam, Sarah L Elkin, Sebastian L Johnston & Patrick Mallia. (2014) Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. The Lancet Respiratory Medicine 2:11, pages 919-932.
Crossref
Crossref
Hammad Qureshi, Amir Sharafkhaneh & Nicola A. Hanania. (2014) Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications. Therapeutic Advances in Chronic Disease 5:5, pages 212-227.
Crossref
Crossref
Andrea Poisson Irani & LeRoi S. Hicks. (2014) Reducing the Readmission Burden of COPD: A Focused Review of Recent Interventions. Current Emergency and Hospital Medicine Reports 2:3, pages 172-181.
Crossref
Crossref
K. Suresh Babu, Jack A. Kastelik & Jaymin B. Morjaria. (2014) Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. British Journal of Clinical Pharmacology 78:2, pages 282-300.
Crossref
Crossref
J.A. Wedzicha, D. Singh, J. Vestbo, P.L. Paggiaro, P.W. Jones, F. Bonnet-Gonod, G. Cohuet, M. Corradi, S. Vezzoli, S. Petruzzelli & A. Agusti. (2014) Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respiratory Medicine 108:8, pages 1153-1162.
Crossref
Crossref
Virginia Norris, Claire Ambery & Trevor Riley. (2014)
Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β
2
-agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers
. Clinical Pharmacology in Drug Development 3:4, pages 305-313.
Crossref
Crossref
Yaa-Hui Dong, Chia-Hsuin Chang, Fe-Lin Lin Wu, Li-Jiuan Shen, Peter M.A. Calverley, Claes-Göran Löfdahl, Mei-Shu Lai & Donald A. Mahler. (2014) Use of Inhaled Corticosteroids in Patients With COPD and the Risk of TB and Influenza. Chest 145:6, pages 1286-1297.
Crossref
Crossref
Kayleigh M Kew, Sofia Dias & Christopher J Cates. (2014) Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Kayleigh M Kew & Alieksei Seniukovich. (2014) Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014:12.
Crossref
Crossref
Peter M.A. Calverley. 2014. Community-Acquired Pneumonia. Community-Acquired Pneumonia
234
242
.
Tricia McKeever, Timothy W. Harrison, Richard Hubbard & Dominick Shaw. (2013) Inhaled Corticosteroids and the Risk of Pneumonia in People With Asthma. Chest 144:6, pages 1788-1794.
Crossref
Crossref
Samy Suissa, Valérie Patenaude, Francesco Lapi & Pierre Ernst. (2013) Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68:11, pages 1029-1036.
Crossref
Crossref
Lucía Marzoratti, Hernán A. Iannella & Grant W. Waterer. (2013) Inhaled corticosteroids and the increased risk of pneumonia. Therapeutic Advances in Respiratory Disease 7:4, pages 225-234.
Crossref
Crossref
Yoshinosuke Fukuchi, Ronnie Samoro, Rustem Fassakhov, Hiroyuki Taniguchi, Jan Ekelund, Lars-Goran Carlsson & Masakazu Ichinose. (2013) Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results. Respirology 18:5, pages 866-873.
Crossref
Crossref
Mark T Dransfield, Sally Lettis, Frank Barnhart, Courtney Crim & Peter M A Calverley. (2013) Fluticasone furoate and vilanterol for COPD – Authors' reply. The Lancet Respiratory Medicine 1:5, pages e21-e22.
Crossref
Crossref
Timothy E. Albertson, Michael Schivo, Amir A. Zeki, Samuel Louie, Mark E. Sutter, Mark Avdalovic & Andrew L. Chan. (2013) The Pharmacological Approach to the Elderly COPD Patient. Drugs & Aging 30:7, pages 479-502.
Crossref
Crossref
Chris Cates. (2013) Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax 68:6, pages 499-500.
Crossref
Crossref
Samy Suissa. (2013) Number needed to treat in COPD: exacerbations versus pneumonias. Thorax 68:6, pages 540-543.
Crossref
Crossref
Mark T Dransfield, Jean Bourbeau, Paul W Jones, Nicola A Hanania, Donald A Mahler, Jørgen Vestbo, Andrew Wachtel, Fernando J Martinez, Frank Barnhart, Lisa Sanford, Sally Lettis, Courtney Crim & Peter MA Calverley. (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. The Lancet Respiratory Medicine 1:3, pages 210-223.
Crossref
Crossref
Kartik V. Shenoy & Gerard J. Criner. 2013. Smoking and Lung Inflammation. Smoking and Lung Inflammation
177
190
.
François Maltais & Julie Milot. (2012) The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 6:6, pages 345-361.
Crossref
Crossref
Luis Javier Nannini, Toby J Lasserson & Phillippa Poole. (2012)
Combined corticosteroid and long-acting beta
2
-agonist in one inhaler versus long-acting beta
2
-agonists for chronic obstructive pulmonary disease
. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Hana Müllerova, Chuba Chigbo, Gerry W. Hagan, Mark A. Woodhead, Marc Miravitlles, Kourtney J. Davis & Jadwiga A. Wedzicha. (2012) The natural history of community-acquired pneumonia in COPD patients: A population database analysis. Respiratory Medicine 106:8, pages 1124-1133.
Crossref
Crossref
Anand A. Dalal, Manan Shah, Anna O. D’Souza & Glenn D. Crater. (2012) Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy. Respiratory Medicine 106:6, pages 829-837.
Crossref
Crossref
José Luis Izquierdo Alonso & José Miguel Rodríguez Glez-Moro. (2012) Utilización excesiva de corticoides inhalados en la enfermedad pulmonar obstructiva crónica. Archivos de Bronconeumología 48:6, pages 207-212.
Crossref
Crossref
Amir Sharafkhaneh, John G. Southard, Mitchell Goldman, Tom Uryniak & Ubaldo J. Martin. (2012) Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study. Respiratory Medicine 106:2, pages 257-268.
Crossref
Crossref
A. Agusti, J. Hedner, J.M. Marin, F. Barbé, M. Cazzola & S. Rennard. (2011) Night-time symptoms: a forgotten dimension of COPD. European Respiratory Review 20:121, pages 183-194.
Crossref
Crossref
Gary T. Ferguson. (2011) Maintenance pharmacotherapy of mild and moderate COPD: What is the Evidence?. Respiratory Medicine 105:9, pages 1268-1274.
Crossref
Crossref
Fernando J Martinez, James F Donohue & Stephen I Rennard. (2011) The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development. The Lancet 378:9795, pages 1027-1037.
Crossref
Crossref
Ana Maria Baptista Menezes, Silvia Elaine Cardozo Macedo, Ricardo Bica Noal, Jussara Fiterman, Alberto Cukier, José Miguel Chatkin & Frederico Leon Arrabal Fernandes. (2011) Tratamento farmacológico da DPOC. Jornal Brasileiro de Pneumologia 37:4, pages 527-543.
Crossref
Crossref
D. M. G. Halpin, J. Gray, S. J. Edwards, J. Morais & D. Singh. (2011) Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. International Journal of Clinical Practice 65:7, pages 764-774.
Crossref
Crossref
A. Vergnenègre & C. Chouaïd. (2011) Aspects médico-économiques de la pneumologie. Revue des Maladies Respiratoires Actualités 3:6, pages 190-201.
Crossref
Crossref
Natya Raghavan, Katherine Webb, Naparat Amornputtisathaporn & Denis E O’Donnell. (2011) Recent advances in pharmacotherapy for dyspnea in COPD. Current Opinion in Pharmacology 11:3, pages 204-210.
Crossref
Crossref
Alison C. Cave & Martin M. Hurst. (2011) The use of long acting β2-agonists, alone or in combination with inhaled corticosteroids, in Chronic Obstructive Pulmonary Disease (COPD). Pharmacology & Therapeutics 130:2, pages 114-143.
Crossref
Crossref
Peter M.A. Calverley, Robert A. Stockley, Terence A.R. Seemungal, Gerry Hagan, Lisa R. Willits, John H. Riley & Jadwiga A. Wedzicha. (2011) Reported Pneumonia in Patients With COPD. Chest 139:3, pages 505-512.
Crossref
Crossref
Thomas Glaab & Christian Taube. (2011) Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 24:1, pages 15-22.
Crossref
Crossref
С. Н. Авдеев. (2010) Ингаляционные глюкокортикостероиды при хронической обструктивной болезни легких. PULMONOLOGIYA:6, pages 109-119.
Crossref
Crossref
Agnes Kliber, Larry D Lynd & Don D Sin. (2010) The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respiratory Research 11:1.
Crossref
Crossref
С. Н. АвдеевГ. Е. Баймаканова. (2010) Ингаляционные глюкокортикостероиды и риск развития
пневмонии у больных хронической обструктивной
болезнью легких. PULMONOLOGIYA:5, pages 101-109.
Crossref
Crossref
Nicola A. Hanania, David M. Mannino, Barbara P. Yawn, Douglas W. Mapel, Fernando J. Martinez, James F. Donohue, Mark Kosinski, Regina Rendas-Baum, Matthew Mintz, Steven Samuels, Priti Jhingran & Anand A. Dalal. (2010) Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respiratory Medicine 104:8, pages 1160-1170.
Crossref
Crossref
A. Anzueto. (2010) Impact of exacerbations on COPD. European Respiratory Review 19:116, pages 113-118.
Crossref
Crossref